Companies › Suzhou BlueHorse Therapeutics
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LM103 TILs Injection Autologous tumor-infiltrating lymphocytes (TILs) extracted, cultured and expanded from pat | – | Phase 2 | Advanced Melanoma; Non-Small Cell Lung Cancer; Melanoma | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07310784 | LM103 TILs Injection | Phase 2 | Advanced Melanoma | Oncology | Dec 2027 |
| NCT07444437 | LM103 TILs Injection | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT05366478 | LM103 TILs Injection | Phase 1 | Melanoma | Oncology | May 2029 |
No annotated target.
–
Vasgene Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics Tessa Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.